DescriptionCurator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf
Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitracin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2364036 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | BACITRACIN Approved UseUses first aid to help prevent infection in: •minor cuts •scrapes •burns Launch Date-6.7616637E11 |
|||
Curative | CORTISPORIN Approved UseFor the treatment of corticosteroid-responsice dermatoses with secondary infection. Launch Date-4.0417919E11 |
|||
Curative | NEOSPORIN Approved UseNEOSPORIN Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. Launch Date-4.7260799E10 |
PubMed
Title | Date | PubMed |
---|---|---|
Bacitracin: Methods of Production, Concentration, and Partial Purification, with a Summary of the Chemical Properties of Crude Bacitracin. | 1948 Feb |
|
The relative antisyphilitic activity of penicillins F,G,K, and X and of bacitracin, based on the amounts required to abort early syphilic infections in rabbits. | 1948 Mar |
|
The Action of Bacitracin and Subtilin on Treponema pallidum in Vitro and in Vivo. | 1948 Mar |
|
The Results of the Systemic Administration of the Antibiotic, Bacitracin, in Surgical Infections: A Preliminary Report. | 1948 Oct |
|
A Note on the Susceptibility of Hemophilus influenzae Type B to Bacitracin. | 1948 Oct |
|
The Use of Bacitracin in Experimental Clostridium Welchii Infection in Guinea Pigs. | 1949 Oct |
|
IN VITRO STUDIES ON POSSIBLE SYNERGISTIC ACTION BETWEEN PENICILLIN AND BACITRACIN. | 1949 Sep |
|
In vitro sensitivity of Bacillus proteus and Pseudomonas aeruginosa to seven antibiotics; penicillin, streptomycin, bacitracin, polymyxin, aerosporin, aureomycin, and chloromycetin. | 1950 Feb |
|
Systemic bacitracin in the treatment of progressive bacterial synergistic gangrene. | 1950 Feb |
|
Detection by HPLC-ICP of metallothionein in serum of an epileptic child with valproate-associated hepatotoxicity. | 1992 Dec |
|
Differential dephosphorylation of the insulin receptor and its 160-kDa substrate (pp160) in rat adipocytes. | 1992 Jul 15 |
|
[Effect of zinc deficiency and zinc replenishment on HOX3.5 gene expression in mouse embryos]. | 2001 Nov |
|
p53 protein and p21 mRNA levels and caspase-3 activity are altered by zinc status in aortic endothelial cells. | 2002 Aug |
|
Zinc depletion reduced Egr-1 and HNF-3beta expression and apolipoprotein A-I promoter activity in Hep G2 cells. | 2002 Aug |
|
Zinc-dependent interaction between dishevelled and the Drosophila Wnt antagonist naked cuticle. | 2002 Dec 13 |
|
S-nitrosothiols react preferentially with zinc thiolate clusters of metallothionein III through transnitrosation. | 2002 Jul 2 |
|
Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. | 2002 Nov |
|
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). | 2002 Oct 25 |
|
Evidence for non-isostructural replacement of Zn(2+) with Cd(2+) in the beta-domain of brain-specific metallothionein-3. | 2002 Sep 11 |
|
Induction of metallothionein by zinc protects from daunorubicin toxicity in rats. | 2002 Sep 30 |
|
Interrelationships among brain, endocrine and immune response in ageing and successful ageing: role of metallothionein III isoform. | 2003 Apr |
|
Effect of chromium on apolipoprotein A-I expression in HepG2 cells. | 2003 Apr |
|
Changes in rat hepatic gene expression in response to zinc deficiency as assessed by DNA arrays. | 2003 Apr |
|
Zinc deficiency induces oxidative DNA damage and increases p53 expression in human lung fibroblasts. | 2003 Aug |
|
Human ZIP1 is a major zinc uptake transporter for the accumulation of zinc in prostate cells. | 2003 Aug 1 |
|
Mechanisms of Zn(2+)-induced signal initiation through the epidermal growth factor receptor. | 2003 Aug 15 |
|
Redox labile site in a Zn4 cluster of Cu4,Zn4-metallothionein-3. | 2003 Aug 19 |
|
The acrodermatitis enteropathica gene ZIP4 encodes a tissue-specific, zinc-regulated zinc transporter in mice. | 2003 Aug 29 |
|
Human peptidoglycan recognition protein-L is an N-acetylmuramoyl-L-alanine amidase. | 2003 Dec 5 |
|
Indomethacin-induced free radical-mediated changes in the intestinal brush border membranes. | 2003 Feb 15 |
|
Pancreatic metallothionein-I may play a role in zinc homeostasis during maternal dietary zinc deficiency in mice. | 2003 Jan |
|
p53 deficiency accelerates induction and progression of esophageal and forestomach tumors in zinc-deficient mice. | 2003 Jan 1 |
|
A novel class of ligand-gated ion channel is activated by Zn2+. | 2003 Jan 10 |
|
Differential effects of zinc on functionally distinct human growth hormone mutations. | 2003 Jul |
|
Chromium(VI) down-regulates heavy metal-induced metallothionein gene transcription by modifying transactivation potential of the key transcription factor, metal-responsive transcription factor 1. | 2003 Jul 11 |
|
In vitro effect of metal ions on the activity of two amphibian glyceraldehyde-3-phosphate dehydrogenases: potential metal binding sites. | 2003 Jun |
|
Zinc accumulation in N-methyl-N-nitrosourea-induced rat mammary tumors is accompanied by an altered expression of ZnT-1 and metallothionein. | 2003 Jun |
|
Copper reduction by copper binding proteins and its relation to neurodegenerative diseases. | 2003 Mar |
|
Interaction of Tl+ with product complexes of fructose-1,6-bisphosphatase. | 2003 May 2 |
|
Zinc modulates mRNA levels of cytokines. | 2003 Nov |
|
Regulated cell surface pro-EGF ectodomain shedding is a zinc metalloprotease-dependent process. | 2003 Nov 14 |
|
Zinc modulates PPARgamma signaling and activation of porcine endothelial cells. | 2003 Oct |
|
Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters. | 2003 Oct 1 |
|
Identification of human intestinal alkaline sphingomyelinase as a novel ecto-enzyme related to the nucleotide phosphodiesterase family. | 2003 Oct 3 |
|
Prion, amyloid beta-derived Cu(II) ions, or free Zn(II) ions support S-nitroso-dependent autocleavage of glypican-1 heparan sulfate. | 2003 Oct 3 |
|
Purification of recombinant human apometallothionein-3 and reconstitution with zinc. | 2003 Sep |
|
O6-alkylguanine-DNA alkyltransferase: low pKa and high reactivity of cysteine 145. | 2003 Sep 23 |
|
Heparin-binding epidermal growth factor cleavage mediates zinc-induced epidermal growth factor receptor phosphorylation. | 2004 Apr |
|
Thymulin evokes IL-6-C/EBPbeta regenerative repair and TNF-alpha silencing during endotoxin exposure in fetal lung explants. | 2004 Mar |
|
Bacitracin Inhibits the Migration of U87-MG Glioma Cells via Interferences of the Integrin Outside-in Signaling Pathway. | 2016 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf
Curator's Comment:: Bacitracin can be used as ophtalmic solution (0.025mg/ml) for the treatment of superficial ocular infections.
400 units, topically
Route of Administration:
Topical
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
1284
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
||
|
WHO-VATC |
QR02AB04
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
||
|
WHO-ATC |
J01XX10
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
||
|
CFR |
21 CFR 333.120
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
||
|
CFR |
21 CFR 524.155
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
||
|
WHO-ATC |
R02AB04
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
||
|
CFR |
21 CFR 556.70
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
||
|
EPA PESTICIDE CODE |
6302
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
||
|
CFR |
21 CFR 333.110
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
||
|
CFR |
21 CFR 524.154
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
||
|
CFR |
21 CFR 520.154
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
||
|
WHO-ATC |
D06AX05
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
||
|
WHO-VATC |
QJ01XX10
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
||
|
WHO-VATC |
QD06AX05
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
||
|
WHO-VATC |
QA07AA93
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
BACITRACIN
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
PRIMARY | |||
|
215-786-2
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
PRIMARY | |||
|
SUB00652MIG
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
PRIMARY | |||
|
1291
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
PRIMARY | RxNorm | ||
|
BACITRACIN
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
PRIMARY | Description: A white or pale brownish yellow powder; odourless or with a faint characteristic odour. Solubility: Freely soluble in water, methanol R and ethanol (~750 g/l) TS; practically insoluble in acetone R and ether R. Category: Antiinfective drug. Storage: Bacitracin should be kept in a tightly closed container, protected from light and stored at a temperature between 2? and8?C. If it is intended for parenteral administration, the container should be sterile and sealed so as to exclude micro-organisms. Labelling: The designation sterile Bacitracin indicates that the substance complies with the additional requirements for sterileBacitracin and may be used for parenteral administration or for other sterile applications. Additional information: Bacitracin is hygroscopic. Its solutions deteriorate rapidly at room temperature. Even in the absence oflight, it is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. | ||
|
DB00626
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
PRIMARY | |||
|
58H6RWO52I
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
PRIMARY | |||
|
C295
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
PRIMARY | |||
|
1167
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
PRIMARY | |||
|
M2197
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
PRIMARY | Merck Index | ||
|
N0000008479
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
PRIMARY | Decreased Cell Wall Synthesis & Repair [PE] | ||
|
Bacitracin
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
PRIMARY | |||
|
D001414
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
PRIMARY | |||
|
1405-87-4
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
PRIMARY | |||
|
CHEMBL1200558
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
PRIMARY | |||
|
281
Created by
admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
|
PRIMARY |
All of the following components must be present:
ACTIVE MOIETY
SALT/SOLVATE (PARENT)